Viracta Therapeutics’ (VIRX) “Outperform” Rating Reaffirmed at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $13.00 target price on the stock.

Separately, HC Wainwright restated a buy rating and issued a $4.00 target price on shares of Viracta Therapeutics in a research note on Tuesday.

Viracta Therapeutics Trading Up 31.9 %

Shares of VIRX opened at $0.94 on Wednesday. Viracta Therapeutics has a 12 month low of $0.43 and a 12 month high of $2.38. The stock has a fifty day moving average price of $0.90 and a 200-day moving average price of $0.70.

Viracta Therapeutics (NASDAQ:VIRX) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.05). As a group, analysts forecast that Viracta Therapeutics will post -1.28 earnings per share for the current year.

Hedge Funds Weigh In On Viracta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VIRX. State Street Corp raised its stake in shares of Viracta Therapeutics by 2.3% during the 1st quarter. State Street Corp now owns 588,603 shares of the company’s stock valued at $2,802,000 after buying an additional 13,514 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Viracta Therapeutics by 94.6% during the 2nd quarter. Renaissance Technologies LLC now owns 93,399 shares of the company’s stock valued at $362,000 after buying an additional 45,399 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Viracta Therapeutics during the 2nd quarter valued at about $1,227,000. Cubist Systematic Strategies LLC purchased a new position in shares of Viracta Therapeutics during the 2nd quarter valued at about $52,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Viracta Therapeutics by 35.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 204,164 shares of the company’s stock valued at $792,000 after buying an additional 53,475 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.